Takeda (TSE:4502/NYSE:TAK), a global values-based R&D-driven biopharmaceutical leader headquartered in Japan, translates science into innovative medicines. It focuses its R&D efforts on four therapeutic areas: oncology, rare diseases, neuroscience and gastroenterology. It also makes R&D investments in plasma-derived therapies and vaccines. Takeda is focusing on developing innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging enhanced collaborative R&D engines and capabilities to create a modality-diverse pipeline. Its employees are committed to improving quality of life for patients and to working with healthcare partners in some 80 countries.
The Centre for Health and Healthcare is identifying and scaling up solutions for more resilient, efficient, and equitable healthcare systems.
The Centre for Nature and Climate is accelerating net-zero climate action, regenerates food, water and ocean systems, and promotes circular economies.
The Centre for the Fourth Industrial Revolution is advancing the application of human-centred and society-serving technologies.
The Centre for the New Economy and Society is providing a platform for leaders to shape inclusive and equitable economies and societies that create opportunity for all.
